GeneDx Holdings Corp. reported an insider ownership change involving Mark A. Gardner, with the reported transaction dated June 29, 2026. The filing describes an award of restricted stock units tied to GeneDx’s Class A common stock. Each restricted stock unit represents a contingent right to receive one share of the company’s Class A common stock upon settlement, and the units are to be settled for no consideration. The award is structured to vest over four years: 25% of the total grant is scheduled to vest annually on each July 1, beginning July 1, 2027. Vesting is subject to Gardner’s continued service to GeneDx through each applicable vesting date. The restricted stock units do not carry an expiration date; instead, they either vest according to the schedule or are canceled before vesting if the service condition is not met. The document text provided does not show the number of restricted stock units granted, the transaction code, the per-share price, or Gardner’s beneficial ownership totals after the transaction. It also does not indicate any open-market purchase or sale of GeneDx stock. The reported action appears to be an equity-compensation grant rather than a cash-market transaction. The filing was signed on July 1, 2026, by Bridget Brown as attorney-in-fact for the reporting person. The key significance is that GeneDx disclosed a new insider equity award that could convert into Class A common shares over time, aligning the recipient’s compensation with the company’s stock performance and continued service.